Health care resource utilization and costs among patients with multiple myeloma with exposure to double-class or triple-class multiple myeloma treatments: A retrospective US claims database analysis
Joseph Yuan‐Mou Yang, Natalie Boytsov, Josh J. Carlson, Douglas Barthold
Abstract
BACKGROUND: Despite recent advancements in the therapeutic landscape, multiple myeloma (MM) remains incurable. There are multiple treatment options available with a novel mechanism of action, but there is limited evidence describing the economic burden among patients with MM exposed to different drug classes and combinations and across different health care settings.
Topics & Concepts
MedicineRetrospective cohort studyMultiple myelomaDrug classHealth careDatabaseCohortInternal medicineEmergency medicineDrugComputer scienceEconomic growthEconomicsPsychiatryMultiple Myeloma Research and TreatmentsChronic Myeloid Leukemia TreatmentsChronic Lymphocytic Leukemia Research